Peripherally targeted analgesia via AAV-mediated sensory neuron–specific inhibition of multiple pronociceptive sodium channels
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci170813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Seung Min Shin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Dependovirus, Sensory Receptor Cells, NAV1.7 Voltage-Gated Sodium Channel. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Dr. Ralph and Marian Falk Medical Research Trust.
Abstract (Originalsprache)
This study reports that targeting intrinsically disordered regions of the voltage-gated sodium channel 1.7 (Na V 1.7) protein facilitates discovery of sodium channel inhibitory peptide aptamers (Na V iPA) for adeno-associated virus–mediated (AAV-mediated), sensory neuron–specific analgesia. A multipronged inhibition of I Na1.7 , I Na1.6 , I Na1.3 , and I Na1.1 — but not I Na1.5 and I Na1.8 — was found for a prototype and named Na V iPA1, which was derived from the Na V 1.7 intracellular loop 1, and is conserved among the TTXs Na V subtypes. Na V iPA1 expression in primary sensory neurons (PSNs) of dorsal root ganglia (DRG) produced significant inhibition of TTXs I Na but not TTXr I Na . DRG injection of AAV6-encoded Na V iPA1 significantly attenuated evoked and spontaneous pain behaviors in both male and female rats with neuropathic pain induced by tibial nerve injury (TNI). Whole-cell current clamp of the PSNs showed that Na V iPA1 expression normalized PSN excitability in TNI rats, suggesting that Na V iPA1 attenuated pain by reversal of injury-induced neuronal hypersensitivity. IHC revealed efficient Na V iPA1 expression restricted in PSNs and their central and peripheral terminals, indicating PSN-restricted AAV biodistribution. Inhibition of sodium channels by Na V iPA1 was replicated in the human iPSC-derived sensory neurons. These results summate that Na V iPA1 is a promising analgesic lead that, combined with AAV-mediated PSN-specific block of multiple TTXs Na V s, has potential as a peripheral nerve–restricted analgesic therapeutic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Physiology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
- Department of Biology, School of Science, Indiana University-Purdue University, Indianapolis, Indiana, USA.
- Department of Orthopedic Surgery, Qingdao Municipal Hospital, Qingdao, China.
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- Dr. Ralph and Marian Falk Medical Research Trust
- National Institute of Neurological Disorders and Stroke
- MCW Therapeutic Accelerator Program
- Advancing a Healthier Wisconsin Endowment Project
Zitieren
APA
Shin, S. M., Itson-Zoske, B., Fan, F., Xiao, Y., Qiu, C., Cummins, T. R., Hogan, Q. H., & Yu, H. (2024). Peripherally targeted analgesia via AAV-mediated sensory neuron–specific inhibition of multiple pronociceptive sodium channels. Journal of Clinical Investigation. https://doi.org/10.1172/jci170813
Vancouver
Shin SM, Itson-Zoske B, Fan F, Xiao Y, Qiu C, Cummins TR, et al. Peripherally targeted analgesia via AAV-mediated sensory neuron–specific inhibition of multiple pronociceptive sodium channels. Journal of Clinical Investigation. 2024. doi:10.1172/jci170813
BibTeX
@article{Shin2024,
author = {Shin, Seung Min and Itson-Zoske, Brandon and Fan, Fan and Xiao, Yucheng and Qiu, Chensheng and Cummins, Theodore R and Hogan, Quinn H and Yu, Hongwei},
title = {Peripherally targeted analgesia via AAV-mediated sensory neuron–specific inhibition of multiple pronociceptive sodium channels},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci170813}
}
EUVIMED